Current Vaccination Practice in Diabetic (Diabetes I) Patients
- Authors: Kumar Y.1, Sundaram S.1, Yadav D.1
-
Affiliations:
- Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India
- Issue: Vol 20, No 4 (2024)
- Section: Medicine
- URL: https://snv63.ru/1573-3998/article/view/642986
- DOI: https://doi.org/10.2174/0115733998260361230927002739
- ID: 642986
Cite item
Full Text
Abstract
The worldwide prevalence of diabetes, an endocrine condition, is rising quickly. The alarming rise of diabetes in recent years has emerged as a major contributor to premature death and illness among persons of working age. The potential use of immunomodulatory drugs to prevent diabetes has been a source of worry in light of recent advances in our understanding of the role of autoimmune responses in the development of diabetes. Vaccines can work in a variety of ways, including by eliminating autoreactive T-cells or by blocking the connections between immune cells. Most diabetes vaccines that have been created so far have only been evaluated in animal models, with just a small number having undergone successful human trials. In this article, the authors also look at the clinical trial research that are currently being conducted to create a prototype diabetes vaccine.
About the authors
Yati Kumar
Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India
Email: info@benthamscience.net
Sonali Sundaram
Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India
Author for correspondence.
Email: info@benthamscience.net
Deepika Yadav
Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India
Email: info@benthamscience.net
Supplementary files
